Jean Cui, Ph.D.
Scientific Founder, President and CEO, BlossomHill Therapeutics, Inc.
Professional Overview
Dr. Jean Cui is a highly accomplished pharmaceutical executive with over 25 years of experience in drug discovery and development. As the Scientific Founder, President and CEO of BlossomHill Therapeutics, Inc., she leverages her deep expertise in oncology and extensive leadership experience to drive the company's mission of developing innovative cancer therapies.
Experience Summary
Current Role
As the Scientific Founder, President and CEO of BlossomHill Therapeutics, Dr. Cui is responsible for establishing the strategic vision and overseeing all aspects of the company's operations. She leads a talented team of scientists and drug development professionals in advancing the company's pipeline of novel cancer treatments, with a focus on precision oncology and immuno-oncology.
Career Progression
Prior to founding BlossomHill Therapeutics, Dr. Cui served as the Scientific Founder and Director of Turning Point Therapeutics, where she played a crucial role in the company's early-stage drug development efforts. Before that, she held the positions of Scientific Founder, Chief Scientific Officer, and Director at Turning Point Therapeutics, and served as an Associate Research Fellow at Pfizer, where she made significant contributions to the company's oncology drug development programs.
Dr. Cui's earlier career also includes roles as a Project Leader and Group Leader at SUGEN, Inc., as well as a Research Scientist at Corvas International, Inc. and Glycomed, Inc.
Academic Background
Dr. Cui holds a Ph.D. in Biochemistry from the University of California, San Diego, where she specialized in cancer biology and signal transduction pathways.
Areas of Expertise
- Oncology drug discovery and development
- Precision medicine and targeted therapies
- Immuno-oncology and cancer immunotherapy
- Translational research and clinical development
- Strategic leadership and team building
- Entrepreneurship and biotechnology company formation
Professional Impact
Under Dr. Cui's leadership, BlossomHill Therapeutics has rapidly advanced its pipeline of innovative cancer treatments, with several candidates in various stages of preclinical and clinical development. Her scientific expertise, strategic vision, and collaborative approach have been instrumental in establishing the company as a promising player in the oncology landscape.
Conclusion
With her exceptional scientific background, extensive industry experience, and proven track record of success, Dr. Jean Cui is poised to continue making significant contributions to the field of cancer research and drug development. As the Scientific Founder, President and CEO of BlossomHill Therapeutics, she is committed to advancing the company's mission of transforming the lives of cancer patients through the development of groundbreaking therapies.
